Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we confirmed that lncRNA SNHG16 was highly expressed in glioma and may exert oncogenic function as a competing endogenous RNA (ceRNA) to regulate EGFR by sponging of miR-373-3p through activating PI3K/AKT pathway, which providing a new insight of the regulatory network of lncRNA SNHG16 in the development of glioma.
|
31226483 |
2020 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.
|
31776938 |
2020 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data firstly demonstrated that CREB1-induced FOXD2-AS1 contributed to glioma progression by upregulating AKT1 via competitively binding to miR-185, providing a novel strategy for targeting FOXD2-AS1 as a potential biomarker and a therapeutic target in glioma patients.
|
30553445 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blot of p21, p27 and AKT indicated the possible role of TRIM44 in regulation AKT pathway in glioma.
|
31605296 |
2019 |
Glioma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SAE1 overexpression induces an increase of the SUMOylation and Ser473 phosphorylation of AKT, which promotes glioma cell growth in vitro and in nude mouse tumor model.
|
31345225 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> The effects of CAPON-L overexpression on glioma cell proliferation are dependent on the AKT/mTOR/P53 activity.
|
31171914 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that IL-17 can promote the proliferation and migration of glioma cells via PI3K/Akt1/NF-κB-p65 activation, and these findings might provide a new insight into glioma pathogenesis.
|
30660646 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The newly identified miR-92a/KLF4/AKT/mTOR axis provides novel insight into the pathogenesis of glioma.
|
31378903 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma.
|
31591377 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that BAS-4 showed potential activity against glioma by inducing apoptosis mediated by ΔΨm loss and AKT pathway disruption, and future studies should further evaluate BAS-4 as a promising antineoplastic agent against glioblastoma.
|
30856536 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells.
|
31214505 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of microRNA-708 promotes cell growth and epithelial-to-mesenchymal transition by activating the SPHK2/AKT/β-catenin pathway in glioma.
|
31171769 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of miR-770 indicates a favorable prognosis and suppresses tumorigenesis by modulating PI3K-AKT pathway in glioma.
|
31002138 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma.
|
29535541 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.
|
29774498 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The circ-CFH/miR-149/AKT1 regulation axis may be a potential target for glioma therapy.
|
30111766 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found significant increases in T-cell expressions of PDK1, PI3K, and p-AKT in T11TS-treated animal groups compared to sharp downregulations in glioma.
|
28608562 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reasons for treatment failure include poor penetration of agents into the brain and observations that blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma.
|
28696243 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of LASP1 expression in miR-377-3p-overexpressing cells attenuated the inhibition of glioma cell malignancy and reversed the dephosphorylation of AKT.
|
30372896 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicated that BCL6 may be a tumor oncogene involved in the progression of glioma via affecting AKT and MAPK signaling pathways.
|
30420967 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, KEGG PathwayFinder by gene correlation analysis was performed on the R2: Genomics Analysis and Visualization Platform, which revealed a high association between Ngb and the phosphatidylinositol 3‑kinase (PI3K)/AKT pathway using glioma data (GSE4290) from the Gene Expression Omnibus database.
|
29207186 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicated that combined treatment of <sup>125</sup>I seeds and SAL achieved enhanced growth inhibition and apoptosis in human glioma in vitro and in vivo through triggering ROS-mediated DNA damage and regulation of MAPKs and AKT pathways, which validated that the combined strategy of using <sup>125</sup>I seeds and SAL could be a highly efficient way to achieve enhanced glioma chemo-radiotherapy.
|
29804240 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway.
|
29997438 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with control group, an increased expression of miR-21, PI3K, AKT, p-AKT, P53, and p-GSK3, and a decreased expression of SPRY1, PTEN, Caspase-3, and Caspase-9 were observed in the glioma group, and no significant differences were found in the expression of GSK3.
|
29316313 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, the association between therapeutic efficacy and putative proapoptotic activity of low-dose BVZ either alone or in combination with a specific inhibitor of AKT called perifosine (PRF), in a glioma model was investigated.
|
28616662 |
2017 |